Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00346216 · ClinicalTrials.gov registry record · Phase 4
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 24,081
- Enrollment target
NCT00346216 is a Phase 4 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 24,081 participants.
The verdict
NCT00346216, a Phase 4 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24,081 participants
- Enrollment target
Study Summary
To answer the question of overall benefit: risk of celecoxib when compared to two most commonly prescribe traditional (non-selective) nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of arthritis pain. For this purpose, patients with osteoarthritis or rheumatoid arthritis with or at risk of developing cardiovascular disease will be recruited. The cardiovascular, gastrointestinal and renal safety and symptomatic benefit in each treatment group will be assessed accordingly.
Interventions
- DRUG Ibuprofen
- DRUG Naproxen
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24,081 participants |
| Start Date | 2006-10-04 |
| Est. Completion | 2016-04-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00346216
The ClinicalTrials.gov registry entry for NCT00346216 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 24,081 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ibuprofen is the first listed.
NCT00346216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00346216 about?
NCT00346216 is a clinical study titled "Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen". To answer the question of overall benefit: risk of celecoxib when compared to two most commonly prescribe traditional (non-selective) nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of arthritis pain. For this purpose, patients with osteoarthritis or rheumatoid arthritis with or at ri...
What is the current status of trial NCT00346216?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24,081 participants. The study started on 2006-10-04. Estimated completion is 2016-04-12.
What interventions are being tested in trial NCT00346216?
The interventions under investigation include: Ibuprofen (DRUG), Naproxen (DRUG), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00346216?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.